DUBLIN, IRELAND--(Marketwire - November 29, 2007) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that the US Food and Drug Administration has given clearance to market the rapid, point-of-care TRIstat™ HbA1c system.
